Roche (OTCMKTS:RHHBY – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.
Profitability
This table compares Roche and PolyPid’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roche | N/A | N/A | N/A |
| PolyPid | N/A | -311.08% | -150.83% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Roche and PolyPid, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roche | 1 | 5 | 5 | 0 | 2.36 |
| PolyPid | 1 | 0 | 3 | 0 | 2.50 |
Risk and Volatility
Roche has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Insider & Institutional Ownership
26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Roche and PolyPid”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roche | $76.45 billion | 4.84 | $15.55 billion | N/A | N/A |
| PolyPid | N/A | N/A | -$34.17 million | ($1.48) | -3.45 |
Roche has higher revenue and earnings than PolyPid.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
